Tech Company Financing Transactions

Sienna Biopharmaceuticals Funding Round

Arch Venture Partners, Altitude Life Science Ventures and Partner Fund Management participated in a $34 million Series A funding round for Sienna Biopharmaceuticals. The round was announced on 4/30/2016.

Transaction Overview

Company Name
Sienna Biopharmaceuticals
Announced On
4/30/2016
Transaction Type
Venture Equity
Amount
$34,000,000
Round
Series A
Investors

Arch Venture Partners (Lead Investor) (Robert Nelsen)

Altitude Life Science Ventures

Partner Fund Management

Proceeds Purpose
Proceeds purposes were not disclosed.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
30699 Russell Ranch Rd. 140
Westlake Village, CA 91362
USA
Phone
818-629-2256
Website
www.siennabio.com
Email Address
Not Recorded
Overview
Sienna Biopharmaceuticals (NASDAQ: SNNA) is a company focused on the discovery, clinical development and commercialization of products in aesthetics and dermatology based on scientific breakthroughs that dramatically improve patient outcomes and physicians' practice of medicine.
Profile
Sienna Biopharmaceuticals LinkedIn Company Profile
Social Media
Sienna Biopharmaceuticals Company Twitter Account
Company News
Sienna Biopharmaceuticals News
Facebook
Sienna Biopharmaceuticals on Facebook
YouTube
Sienna Biopharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Frederick Beddingfield
  Frederick Beddingfield LinkedIn Profile  Frederick Beddingfield Twitter Account  Frederick Beddingfield News  Frederick Beddingfield on Facebook
Chief Financial Officer
John Smither
  John Smither LinkedIn Profile  John Smither Twitter Account  John Smither News  John Smither on Facebook
Chief Medical Officer
Paul Lizzul
  Paul Lizzul LinkedIn Profile  Paul Lizzul Twitter Account  Paul Lizzul News  Paul Lizzul on Facebook
Chief Scientific Officer
Silvio Traversa
  Silvio Traversa LinkedIn Profile  Silvio Traversa Twitter Account  Silvio Traversa News  Silvio Traversa on Facebook
Vice President
Debra Condino
  Debra Condino LinkedIn Profile  Debra Condino Twitter Account  Debra Condino News  Debra Condino on Facebook
VP - Bus. Development
Todd Harris
  Todd Harris LinkedIn Profile  Todd Harris Twitter Account  Todd Harris News  Todd Harris on Facebook
VP - Bus. Development
Caroline Hove
  Caroline Hove LinkedIn Profile  Caroline Hove Twitter Account  Caroline Hove News  Caroline Hove on Facebook
VP - General Counsel
Timothy Andrews
  Timothy Andrews LinkedIn Profile  Timothy Andrews Twitter Account  Timothy Andrews News  Timothy Andrews on Facebook
VP - Operations
Majed Kheir
  Majed Kheir LinkedIn Profile  Majed Kheir Twitter Account  Majed Kheir News  Majed Kheir on Facebook
VP - Regulatory Affairs
Ryan Irvine
  Ryan Irvine LinkedIn Profile  Ryan Irvine Twitter Account  Ryan Irvine News  Ryan Irvine on Facebook
VP - Regulatory Affairs
Diane Stroehmann
  Diane Stroehmann LinkedIn Profile  Diane Stroehmann Twitter Account  Diane Stroehmann News  Diane Stroehmann on Facebook

 

 

Browse more venture capital transactions:

Prev: 4/30/2016: nanit venture capital transaction
Next: 4/30/2016: FLX Bio venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.